Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for STELARA® (ustekinumab) for the treatment of adolescents (12 years of age

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In